ログイン
Language:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. C100 医学部/医学系研究科
  2. C100b 刊行物
  3. Nagoya journal of medical science
  4. 87(1)

A case of severe immune-related adverse events, myocarditis with myositis, and myasthenia gravis overlap syndrome following adjuvant nivolumab administration for muscle-invasive bladder cancer

https://doi.org/10.18999/nagjms.87.1.156
https://doi.org/10.18999/nagjms.87.1.156
284a2085-5221-49b3-85b0-8dc2da288b0f
名前 / ファイル ライセンス アクション
14_Kamikawa.pdf 14_Kamikawa.pdf (20.9 MB)
license.icon
アイテムタイプ itemtype_ver1(1)
公開日 2025-03-04
タイトル
タイトル A case of severe immune-related adverse events, myocarditis with myositis, and myasthenia gravis overlap syndrome following adjuvant nivolumab administration for muscle-invasive bladder cancer
言語 en
著者 Kamikawa, Hiroki

× Kamikawa, Hiroki

en Kamikawa, Hiroki

Search repository
Matsukawa, Yoshihisa

× Matsukawa, Yoshihisa

en Matsukawa, Yoshihisa

Search repository
Nishii, Hisae

× Nishii, Hisae

en Nishii, Hisae

Search repository
Naito, Yushi

× Naito, Yushi

en Naito, Yushi

Search repository
Obara, Kazuki

× Obara, Kazuki

en Obara, Kazuki

Search repository
Sahashi, Kentaro

× Sahashi, Kentaro

en Sahashi, Kentaro

Search repository
Morimoto, Ryota

× Morimoto, Ryota

en Morimoto, Ryota

Search repository
Matsuo, Kazuna

× Matsuo, Kazuna

en Matsuo, Kazuna

Search repository
Ishida, Shohei

× Ishida, Shohei

en Ishida, Shohei

Search repository
Inoue, Satoshi

× Inoue, Satoshi

en Inoue, Satoshi

Search repository
Miyagi, Shohei

× Miyagi, Shohei

en Miyagi, Shohei

Search repository
Sakakibara, Ayako

× Sakakibara, Ayako

en Sakakibara, Ayako

Search repository
Katsuno, Masahisa

× Katsuno, Masahisa

en Katsuno, Masahisa

Search repository
Karube, Kennosuke

× Karube, Kennosuke

en Karube, Kennosuke

Search repository
Akamatsu, Shusuke

× Akamatsu, Shusuke

en Akamatsu, Shusuke

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
権利情報Resource http://creativecommons.org/licenses/by-nc-nd/4.0/
権利情報 Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
言語 en
キーワード
主題Scheme Other
主題 immune checkpoint inhibitors
キーワード
主題Scheme Other
主題 immune-related adverse events
キーワード
主題Scheme Other
主題 IM3OS
キーワード
主題Scheme Other
主題 bladder cancer
キーワード
主題Scheme Other
主題 adjuvant therapy
内容記述
内容記述タイプ Abstract
内容記述 Herein, we present a case of severe immune-related adverse events (irAEs), myocarditis with myositis, and myasthenia gravis overlap syndrome (IM3OS) in a patient receiving an immune checkpoint inhibitor (ICI), as adjuvant therapy after surgery for muscle-invasive bladder cancer. An 80-year-old woman who had undergone a total cystectomy for bladder cancer presented with ptosis, diplopia, and paralysis 18 days after receiving nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody, as adjuvant therapy for the first time. Initial testing revealed positive findings on the ice pack test; elevated troponin, creatine kinase, and aldolase levels; and an abnormal electrocardiogram, suggesting that the patient had developed ICI-related myocarditis, myositis, and myasthenia gravis. Despite treatment with intravenous immunoglobulin (IVIG) and high-dose corticosteroids, her condition worsened, leading to a complete atrioventricular block. After cardiac pacemaker insertion and intensive treatment with repeated high-dose corticosteroids, IVIG, plasma exchange, and tacrolimus, left ventricular function and myositis symptoms improved. However, the patient developed a respiratory infection and renal failure, leading to death on day 99. Although ICIs are considered relatively safe with few side effects, they can cause serious complications and lead to death. In particular, when severe irAEs occur in multiple organs, such as IM3OS, the prognosis is poor. Although IM3OS has no specific diagnostic biomarker, making early detection difficult, clinicians should always pay attention to patient symptoms when using ICI and evaluate other pathologies with IM3OS when conditions such as myositis or myocarditis are suspected. Further research is needed to elucidate the pathophysiology and risk factors of IM3OS.
言語 en
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語 en
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
ID登録
ID登録 10.18999/nagjms.87.1.156
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/871.html
収録物識別子
収録物識別子タイプ PISSN
収録物識別子 0027-7622
収録物識別子
収録物識別子タイプ EISSN
収録物識別子 2186-3326
書誌情報 en : Nagoya Journal of Medical Science

巻 87, 号 1, p. 156-162, 発行日 2025-02
戻る
0
views
See details
Views

Versions

Ver.1 2025-03-04 01:24:49.023205
Show All versions

Share

Share
tweet

Cite as

Other

print

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX
  • ZIP

コミュニティ

確認

確認

確認


Powered by WEKO3


Powered by WEKO3